RE: Incase anyone missed..................21 Sep 2023 11:36
MD, Chairman and CEO of Apollon stated, "I am extremely pleased to proceed forward to complete this transaction for Sproutly to acquire Apollon's assets. I believe the combination of assets currently held by the two companies will demonstrate that the whole is more than the sum of the parts. Together these assets include multiple synergistic drug discovery technologies, pending patents and proprietary intellectual property, successful pre-clinical and clinical testing, manufacturing and production laboratories, existing exclusive global licenses and sales agreements in numerous countries which we expect to generate significant royalty revenue, and the ability to develop new combinatorial therapeutic products. I look forward to working with Dr. in building what I believe will be a leading natural biologics drug discovery company developing new therapeutic products for near term international distribution and sales".Stephen D. BarnhillArup Sen